Is Coloplast A/S a good investment? Coloplast A/S (CBHD.DE) is currently trading at 53.96 EUR.
In terms of valuation, the stock trades at a P/E ratio of 42.83. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Coloplast A/S is expected to release its next earnings report on Aug. 18, 2026.
For income investors, Coloplast A/S pays a dividend yield of 5.74%. With a payout ratio of 130%, the dividend appears to be under pressure.
Yes, it pays an annual dividend of 23.00 EUR (5.74% yield).
Coloplast A/S is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Aug. 18, 2026. The company currently has a trailing EPS of 1.25.
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
5.74% (5y avg: 2.54%)
23.00 EUR
May 18, 2026
129.96%
| Year | Total Dividends |
|---|---|
| 2026 | 3.24 EUR |
| Dec. 10, 2026 (estimated) | 2.5760 |
| May 20, 2026 | 0.6620 |
| 2025 | 3.08 EUR |
| Dec. 9, 2025 | 2.4089 |
| May 12, 2025 | 0.6691 |
| 2024 | 2.95 EUR |
| Dec. 10, 2024 | 2.2758 |
| May 15, 2024 | 0.6694 |
| 2023 | 2.81 EUR |
| Dec. 12, 2023 | 2.1419 |
| May 17, 2023 | 0.6694 |
| 2022 | 2.68 EUR |
| Dec. 6, 2022 | 2.0081 |
| May 11, 2022 | 0.6694 |
| 2021 | 2.54 EUR |
| Dec. 7, 2021 | 1.8742 |
| May 12, 2021 | 0.6694 |
| 2020 | 2.41 EUR |
| Dec. 8, 2020 | 1.7403 |
| May 13, 2020 | 0.6694 |
| 2019 | 2.28 EUR |
| Dec. 10, 2019 | 1.6064 |
| May 8, 2019 | 0.6694 |
| 2018 | 2.14 EUR |
| Dec. 10, 2018 | 1.4726 |
| May 9, 2018 | 0.6694 |
| 2017 | 2.01 EUR |
| Dec. 12, 2017 | 1.4056 |
| May 10, 2017 | 0.6024 |
| 2016 | 1.81 EUR |
| Dec. 8, 2016 | 1.2048 |
| May 11, 2016 | 0.6024 |
| 2015 | 1.67 EUR |
| Dec. 14, 2015 | 1.0710 |
| May 11, 2015 | 0.6024 |
| 2014 | 1.61 EUR |
| Dec. 9, 2014 | 1.0040 |
| May 9, 2014 | 0.6024 |
| 2013 | 3.94 EUR |
| Dec. 6, 2013 | 0.9371 |
| May 6, 2013 | 3.0000 |
| 2012 | 2.68 EUR |
| Dec. 12, 2012 | 2.6774 |
| 2011 | 1.87 EUR |
| Dec. 8, 2011 | 1.8742 |
| 2010 | 1.34 EUR |
| Dec. 2, 2010 | 1.3387 |
| 2009 | 0.94 EUR |
| Dec. 2, 2009 | 0.9371 |
| 2008 | 0.80 EUR |
| Dec. 18, 2008 | 0.8032 |
| 2007 | 1.20 EUR |
| Dec. 19, 2007 | 1.2048 |
Yearly aggregated dividends
|
Coloplast A/S
May 20, 2026 Upcoming
Dividend
0.662 EUR |
|
Coloplast A/S
Dec 09, 2025 Paid
Dividend
2.4089 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 19, 2012 | 5.000000 |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion